Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.
复制标题
DOI：
10.2337/dc21-0300
复制
发表时间：
2021-08
期刊：
影响因子：
16.2
通讯作者：
DAPA-CKD Trial Committees and Investigators
中科院分区：
文献类型：
--
作者：
Persson F;Rossing P;Vart P;Chertow GM;Hou FF;Jongs N;McMurray JJV;Correa-Rotter R;Bajaj HS;Stefansson BV;Toto RD;Langkilde AM;Wheeler DC;Heerspink HJL;DAPA-CKD Trial Committees and Investigators
The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular outcomes with dapagliflozin versus placebo in participants with chronic kidney disease (CKD) with and without diabetes. We compared outcomes according to baseline glycemic status. We enrolled participants with CKD, estimated glomerular filtration rate (eGFR) 25–75 mL/min/1.73 m2, and urinary albumin-to-creatinine ratio 200–5,000 mg/g. The primary composite end point was sustained eGFR decline ≥50%, end-stage kidney disease, or kidney or cardiovascular death. Of 4,304 participants, 738 had normoglycemia, 660 had prediabetes, and 2,906 had type 2 diabetes. The effect of dapagliflozin on the primary outcome was consistent (P for interaction = 0.19) in normoglycemia (hazard ratio [HR] 0.62 [95% CI 0.39, 1.01]), prediabetes (HR 0.37 [0.21, 0.66]), and type 2 diabetes (HR 0.64 [0.52, 0.79]). We found no evidence for effect modification on any outcome. Adverse events were similar, with no major hypoglycemia or ketoacidosis in participants with normoglycemia or prediabetes. Dapagliflozin safely reduced kidney and cardiovascular events independent of baseline glycemic status.
登录
查看更多内容
影响因子：
3.9
作者：
Eickhoff, Mie K.;Dekkers, Claire C. J.;Heerspink, Hiddo J. L.
通讯作者：
Heerspink, Hiddo J. L.
影响因子：
8.2
作者：
Faerch, Kristine;Blond, Martin B.;Jorgensen, Marit E.
通讯作者：
Jorgensen, Marit E.
影响因子：
37.8
作者：
Anker SD;Butler J;Filippatos G;Khan MS;Marx N;Lam CSP;Schnaidt S;Ofstad AP;Brueckmann M;Jamal W;Bocchi EA;Ponikowski P;Perrone SV;Januzzi JL;Verma S;Böhm M;Ferreira JP;Pocock SJ;Zannad F;Packer M
通讯作者：
Packer M
影响因子：
19.6
作者：
Li, JingWei;Neal, Bruce;Heerspink, Hiddo J. L.
通讯作者：
Heerspink, Hiddo J. L.
影响因子：
158.5
作者：
Heerspink, Hiddo J. L.;Stefansson, Bergur V.;Wheeler, David C.
通讯作者：
Wheeler, David C.